The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

In pancreatic cancer, pelareorep previously demonstrated a strong efficacy signal when administered with gemcitabine, nab-paclitaxel and atezolizumab. Our new safety data indicate its ability to also ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

Artbio, a clinical-stage radiopharmaceutical company, named Johnson & Johnson alum Margaret Yu as chief medical officer. Saisei Ventures tapped Dr. Sven Kili as partner. OSE Immunotherapeutics ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

The revision follows the announcement made by GlaxoSmithKline (NYSE:GSK) regarding its acquisition of IDRx, Inc., a clinical-stage biopharmaceutical firm specializing in precision therapeutics for ...

Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.

London: GSK plc has announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company developing precision therapeutics for ...

British drug maker GSK on Monday said it will buy US biopharmaceutical company IDRx for up to $1.15 billion. The Boston-based biotechnology firm is developing therapeutics for the treatment of ...